📰 John Koconis News
John Koconis News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from John Koconis. Real-time updates on events, politics, business and more.
November 29, 2023
WARREN, N.J., Nov. 29, 2023 -- Timber Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan...
September 18, 2023
WARREN, NJ, Sept. 18, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (
August 22, 2023
LEO Pharma has acquired Timber Pharmaceuticals, in a deal that will add an ‘attractive’ late stage asset to its pipeline in medical dermatology, the company said.
July 3, 2023
WARREN, NJ, July 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a...
March 31, 2023
- Lead asset TMB-001 is only compound to receive official orphan drug designation from European Commission for two severe subtypes of congenital...
February 27, 2023
Timber Pharmaceuticals has received orphan drug designation from the European Commission (EC) for TMB-001 to treat X-linked recessive ichthyosis (XLRI).
February 24, 2023
24.02.2023 - Company Progressing With Pivotal Phase 3 ASCEND Clinical Trial in the U.S., Canada, Italy, France, and Germany BASKING RIDGE, NJ, Feb. 24, 2023 (GLOBE NEWSWIRE) - via NewMediaWire – Timber Pharmaceuticals, Inc. (Timber or the “Company”) ... Seite 1
September 14, 2022
14.09.2022 - European Commission expected to issue its decision on orphan designation in approximately 30 days BASKING RIDGE, NJ, Sept. 14, 2022 (GLOBE NEWSWIRE) - via NewMediaWire - Timber Pharmaceuticals, Inc. (Timber or the “Company”) (NYSE ... Seite 1
August 29, 2022
Press release content from NewMediaWire. The AP news staff was not involved in its creation.
August 29, 2022
- Company announces positive clinical data of FDA-Designated Breakthrough Therapy TMB-001 demonstrating safety, efficacy and quality of life improvements...